Urokinase-type Plasminogen Activator Promotes Synaptic Recovery in the Ischemic Brain.

Manuel Yepes

Open access · diamondAbstract read

In one paragraph

Article in Journal of translational neurosciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 47% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Urokinase-type plasminogen activator protects human umbilical vein endothelial cells from apoptosis in sepsis.International journal of clinical and experimental pathology · 2019
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Manuel YepesDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Atlanta, GA, USA.

Emory University · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026

$167.0M

Urokinase-type Plasminogen Activator in the Ischemic BrainR01NS091201 · NINDS · EMORY UNIVERSITY · PI YEPES, MANUEL SALVADOR · 2015 to 2022

$2.7M

tPA is a Neuroprotectant in the Ischemic BrainR01NS079331 · NINDS · EMORY UNIVERSITY · PI YEPES, MANUEL SALVADOR · 2013 to 2017

$1.7M

TPA Protects the Synapse in the Iscemic BrainI01BX003441 · VA · VETERANS HEALTH ADMINISTRATION · PI YEPES, MANUEL SALVADOR · 2017 to 2025

–

BLRD VA I01 BX003441NIH HHS P51 OD011132NINDS NIH HHS R01 NS079331NINDS NIH HHS R01 NS091201

6 · The paper itself

Abstract

Synaptic dysfunction underlies the development of neurological impairment following an acute ischemic stroke. Unfortunately, to this date there is no therapeutic approach to protect and repair the synapse that has suffered an ischemic injury. However, recent research with

Identifiers

PMID29938252

PMCPMC6013270

OpenAlexW2810270726

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.